Histological response to interferon alfa-based therapies in hepatitis C

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 2, 2004, Pages 55-60

  Lee, Samuel S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cirrhosis; Fibrosis; Liver biopsy; Peginterferon; Treatment

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW;

EID: 4444255513     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832929     Document Type: Review

References (40)

1. Lindsay KL, Trepo C, Heintges T, et al. A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
2. Zeuzem S, Feinman SV, Rasenack JZ, et al. Peginterferon Alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672
3. Manns MP, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
5. Poynard T, Bedossa P, Opolon P. Natural history and prognostic factors for chronic hepatitis C. Lancet 1997;349:825-832
6. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-1466
7. Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001;8:249-255
8. Saadeh S, Cammell G, Carey WD, et al. The role of liver biopsy in chronic hepatitis C. Hepatology 2001;33:196-200
9. Knodell RG, Ishak KG, Black WC. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
10. Scheuer P. Classification of chronic viral hepatitis. A need for reassessment. J Hepatol 1991;13:372-374
11. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699
12. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20
13. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680
14. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438
15. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
16. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432
17. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785
18. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-477
19. Neuman M, Benhamou J-P, Bourliere M, et al. Transforming growth factor levels in chronic hepatitis C reflect the degree of fibrosis: role of therapy with pegylated interferon in reducing fibrosis score. Hepatology 2001;34:426A
20. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b plus ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122: 1303-1313
21. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122:1525-1528
22. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-1172
23. Di Bisceglie AM, Bonkovsky HL, Deinstag JL, et al. Design of the HALT-C trial (hepatitis C antiviral long-term treatment to prevent cirrhosis). Gastroenterology 2000;118(suppl 2): 1435A
24. Romagnuolo J, Jhangri GS, Jewell LD, Bain VG. Predicting the liver histology in chronic hepatitis C: how good is the clinician? Am J Gastroenterol 2001;96:3165-3174
25. Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96:3142-3146
26. Patel K, Gordon SC, Oh E, Smith K, McHutchison JG. A non-invasive panel of serum fibrosis markers can reliably differentiate hepatitis C patients with minimal fibrosis from those with fibrosis stages F2-F4. Hepatology 2002;36:355A
27. Dayhoff JE, DeLeo JM. Artificial neural networks: opening the black box. Cancer 2001;91:1615-1635
28. Haydon GH, Jalan R, Ala-Korpela M, et al. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. J Viral Hepat 1998;5:255-264
29. Yamada M, Fukuda Y, Koyama Y, et al. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996;11:646-651
30. Ninomiya T, Yoon S, Hayashi Y, et al. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system. J Gastroenterol Hepatol 1998;13:68-74
31. Fabris P, Marranconi F, Bozzola L, et al. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. J Gastroenterol 1999;34:345-350
32. Itoh Y, Okanoue T, Ohnishi N, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1999;94:1332-1340
33. Mitsuda A, Suou T, Ikuta Y, Kawasaki H. Changes in serum tissue inhibitor or matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C. J Hepatol 2000;32: 666-672
34. Kojima H, Hongo Y, Harada H, et al. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J Gastroenterol Hepatol 2001;16:1015-1021
35. Leroy V, De Traversay C, Barnoud R, et al. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha. J Hepatol 2001;35:120-126
36. Serejo F, Costa A, Oliveira AG, et al. Alfa-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. Dig Dis Sci 2001;46:1684-1689
37. Ueno T, Ide T, Hashimoto O, et al. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers. Hepatogastroenterology 2001;48:1124-1128
38. George J. Biochemical markers of hepatic fibrogenesis: single measurements are not reliable enough to replace liver biopsy. J Gastroenterol Hepatol 2000;15:819-821
39. Kanzler S, Baumann M, Schirmacher P, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001;8:430-437
40. Neuman M, Benhamou I, Akremi R, et al. Serum tumor necrosis factor level in chronic hepatitis C. J Hepatol 2001;34: 108-109